Interleukin-based anti-cancer therapy: Interleukin-37 (IL-37) increases the expression of BTG2 via down regulation of its target gene, 08/March/2015, 17.13

MiRNA-based Immune enhancement therapy: Lin-28 increases SOX2 expression and promotes innate immunity against bacterial infection via down regulation of its target gene, 08/March/2015, 16.47
March 8, 2015
Vitamin-based therapy for Metastatic tumors: 1,25-dihydroxyvitamin D decreases the expression of PD-1, a suppressor of activation of T-cells, and activates the immune system via down regulation of its target gene, 8/March/2015, 22.28
March 8, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Web: http://genomediscovery.org

Significance:  This study suggests, for the first time, Interleukin-37 (IL-37), by suppressing the expression of its target gene, it may increase the expression of tumor suppressor BTG2. Thus, pharmacological formulations encompassing “IL-37 or its activators”  can be used to inhibit the progression of human tumors.

CitationBoominathan, Interleukin-based anti-cancer therapy: Interleukin-37 (IL-37) increases the expression of BTG2 via down regulation of its target gene, 08/March/2015,  17.13, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Undisclosed information: How IL-37 increases the expression of tumor suppressor BTG2

* Research cooperation

Comments are closed.